Clinical trials: sponsored by Acerta Pharma BV

Mantle Cell Lymphoma

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

• Withdrawn
• Age: 18 years and older
• Phase 3

This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Trial name

NCT02735876

Testing

acalabrutinib, ibrutinib, rituximab

Sponsor

Acerta Pharma BV